Federal Register of Legislation - Australian Government

Primary content

This instrument gives effect to a decision to exercise partial Ministerial discretion for a 1 October 2022 Pharmaceutical Benefits Scheme price reduction.
Administered by: Health and Aged Care
Registered 30 Sep 2022

Commonwealth Coat of Arms of Australia

 

PB 97 of 2022

National Health (October 2022 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2022

National Health Act 1953

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care make this determination under subsection 99ADHB(6) of the National Health Act 1953.

Dated         29 September 2022

 

 

 

 

 

 

 

 

 

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care

 

 

 

 

 

 

 

1  Name of Determination

         (1)   This instrument is the National Health (October 2022 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2022.  

         (2)   This instrument may also be cited as PB 97 of 2022.

2  Commencement

                This instrument commences on 1 October 2022.

3  Definition

              Note: A number of expressions used in this instrument are defined in Part VII the Act,

 

In this instrument:

  

   Act means the National Health Act 1953.

4  Authority

This instrument is made under subsection 99ADHB(6) of the Act.

5  Brand of pharmaceutical item with approved ex-manufacturer price not reduced

I determine under subsection 99ADHB(6) of the Act that, for the purposes of subsection 99ADHB(2), the approved ex-manufacturer price that comes into force on 1 October 2022 of the brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 1 is to be worked out using a reduction of 6%.

 


Schedule 1 Brand of pharmaceutical item with approved ex-manufacturer price reduced by 6%

 

Column 1

Column 2

Item

Brand of Pharmaceutical Item

 

Drug

Form

Manner of administration

Brand

1

Sacubitril with valsartan

Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg

Oral

Entresto

2

Sacubitril with valsartan

Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg

Oral

Entresto